Patiromer — Membership Pricing

Other medications in Nephrology

• Sevelamer
• Sodium Zirconium Cyclosilicate
• Sucroferric Oxyhydroxide
• Lanthanum Carbonate

What Patiromer is approved for (FDA label)

Veltassa is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] . Veltassa is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. ( 1 ) Limitation of Use Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: January 31, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Patiromer (FDA label)

Veltassa is an off-white to light-brown powder for oral suspension packaged in single-use packets containing 1 gram, 8.4 grams, 16.8 grams or 25.2 grams patiromer. Powder: 1 gram, 8.4 grams, 16.8 grams and 25.2 grams patiromer packets. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: bf002984-d6c9-46df-aecb-a07733f763c1. SPL document ID: 3e4b6452-1c7c-4f58-aee4-12fb185aaa83. Label effective date: January 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Patiromer (FDA label)

The following adverse reaction is discussed in greater detail elsewhere in the label: Hypomagnesemia [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence ≥ 2%) are constipation, hypomagnesemia, diarrhea, nausea, abdominal discomfort and flatulence. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Vifor Pharma, Inc. at 1-844-VELTASSA (1-844-835-8277) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Veltassa cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: bf002984-d6c9-46df-aecb-a07733f763c1. SPL document ID: 3e4b6452-1c7c-4f58-aee4-12fb185aaa83. Label effective date: January 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Patiromer (FDA label)

Veltassa is contraindicated in patients with a history of a hypersensitivity reaction to Veltassa or any of its components [see Adverse Reactions (6.1) ]. Known hypersensitivity to Veltassa or any of its components. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: bf002984-d6c9-46df-aecb-a07733f763c1. SPL document ID: 3e4b6452-1c7c-4f58-aee4-12fb185aaa83. Label effective date: January 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Patiromer (FDA label)

Worsening of Gastrointestinal Motility. ( 5.1 ) Hypomagnesemia. ( 5.2 ) 5.1 Worsening of Gastrointestinal Motility Avoid use of Veltassa in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, because Veltassa may be ineffective and may worsen gastrointestinal conditions. Patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders were not included in the clinical studies. 5.2 Hypomagnesemia Veltassa binds to magnesium in the colon, which can lead to hypomagnesemia. In clinical studies, hypomagnesemia was reported as an adverse reaction in 5.3% of adult patients treated with Veltassa [see Adverse Reactions (6.1) ]. Monitor serum magnesium. Consider magnesium supplementation in patients who develop low serum magnesium levels on Veltassa.

Source: FDA prescribing information (DailyMed). Set ID: bf002984-d6c9-46df-aecb-a07733f763c1. SPL document ID: 3e4b6452-1c7c-4f58-aee4-12fb185aaa83. Label effective date: January 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Patiromer (FDA label)

Veltassa has the potential to bind some oral co-administered medications, which could decrease their gastrointestinal absorption. Binding of Veltassa to other oral medications not listed in Table 3 below could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time Veltassa is administered. Administer other oral medications at least 3 hours before or 3 hours after Veltassa [see Dosage and Administration (2.1) and Clinical Pharmacology (12.3) ] . Take other orally administered drugs at least 3 hours before or 3 hours after Veltassa except those shown to not have a clinically important interaction. ( 2.1 , 7 ) 7.1 Clinically Important Interaction of Veltassa with Other Drugs The in-vitro binding of the following drugs to patiromer was evaluated and potentially clinically significant binding was observed.

Source: FDA prescribing information (DailyMed). Set ID: bf002984-d6c9-46df-aecb-a07733f763c1. SPL document ID: 3e4b6452-1c7c-4f58-aee4-12fb185aaa83. Label effective date: January 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.